Review Article

Current Updates on Oxazolidinone and Its Significance

Neha Pandit,1 Rajeev K. Singla,2 and Birendra Shrivastava1

1 Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura-Jaipur, Rajasthan 302025, India
2 Sadbhavna College of Management & Technology, Jalaldival, Ludhiana-Barnala State Highway-13, Raikot (Ludhiana), Punjab, India

Correspondence should be addressed to Rajeev K. Singla, rajeevsingla26@gmail.com

Received 22 June 2011; Revised 16 October 2011; Accepted 20 October 2011

Academic Editor: Paola Fossa

Copyright © 2012 Neha Pandit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxazolidinone is a five-member heterocyclic ring exhibiting potential medicinal properties with preferential antibacterial activity. Scientists reported various synthetic procedures for this heterocyclic structure. Current review articles tried to cover each and every potential aspect of oxazolidinone like synthetic routes, pharmacological mechanism of action, medicinal properties, and current research activities.

1. Introduction

The oxazolidinones are a new class of antimicrobial agents which have a unique structure and good activity against gram-positive pathogenic bacteria. Oxazolidinones are a class of compounds containing 2-oxazolidine in the structure. Oxazolidinones represent a new class of synthetic antibacterial agents active against multiple-resistant gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant streptococci, and vancomycin-resistant enterococci [1].

1.1. Chemical Structure [2]. Oxazolidinones are a class of azoles, oxazolidines with the carbon between the nitrogen and oxygen oxidized to a ketone, hence oxazolidinone (Figure 1).

1.2. Nomenclature. The antibacterial oxazolidinone template has a common nomenclature specially for aryl-5-(substituted) methyl-2-oxazolidinone. Throughout the paper, a consistent numbering system has been employed for description of the various oxazolidinone examined [3].

2. Synthetic Schemes

Earlier reviews have comprehensively covered the many synthetic approaches available for construction of the oxazolidinone ring. The most recent literature is replete with accounts of oxazolidinone templates that have seen extensive use as chiral auxiliaries.

(1) Chiral Resolution Method. Early work relied upon chiral resolution as a means to optically active oxazolidinone. The amino-diol resulting from reaction of an aniline with glycidol was resolved using (R)-mandelic acid. Diethylcarb onate effected cyclization to the 5-(R)-hydroxymethyl-3-phenyl-2-oxazolidinone. Numerous approaches had been employed for converting the 5-(R)-methylalcohol moiety to the 5-(S)-acetamidomethyl group. Here tosylation of the alcohol was followed by azide displacement, reduction, and acylation of the amine [4] (Figure 2).

(2) Iodocyclocarbamation. Many of the Upjohn SAR studies were carried out with racemic oxazolidinone, synthesized by iodocyclocarbamation. A key modification was the addition of pyridine, crucial for circumventing untoward alkylative side reaction [5] (Figure 3).

(3) DuPONT Asymmetric Synthesis. The Herwhe-Kauffmann/Speranza-Peppel Method. This method involved high-temperature catalyst-mediated cyclization of an aryl isocyanate with an epoxide where LiBr catalyst was solubilized in refluxing xylene by tributylphosphine oxide. As demonstrated for DuP721 (R)-glycidol butyrate was cyclized with 4-acetylphenyl isocyanate, giving the oxazolidinone butyrate ester. Saponification provided the 5-(R)-hydroxymethyl oxazolidinone which was further
The present reaction can be widely applied to convenient synthesis of useful N-substituted oxazolidinones and chiral oxazinanone intermediate via a bicyclo[2.2.1]intermediate. A reaction mechanism was proposed that the oxazolidinone was obtained from an oxazinanone intermediate via a bicyclo[2.2.1]intermediate.

Various N-Boc-protected alkynylamines were converted into the corresponding alkylidene 2-oxazolidinones or 2-oxazinones under very mild reaction conditions in the presence of a cationic Au(I) complex in high yield regardless of the substitution at nitrogen and alkyne terminus.

(8) A nickel-catalyzed cycloaddition of aziridines with isocyanates proceeded smoothly to give iminooxazolidinone derivatives in good yields. A longer reaction time allowed the isomerization of the iminooxazolidine to the corresponding imidazolidinone derivatives.

(9) Synthesis of Oxazolidinones by the Use of Halomethyloxiranes, Primary Amine, and Carbonate Salt. Primary amines reacted with carbonate salts (Na₂CO₃, K₂CO₃, Cs₂CO₃, and Ag₂CO₃) and halomethyloxiranes in the presence of a base such as DBU or TEA to give oxazolidinones in high yields. The use of K₂CO₃ among these carbonate gave the best yield in this synthesis. A reaction mechanism was proposed that the oxazolidinone was obtained from an oxazinanone intermediate via a bicyclo[2.2.1]intermediate.

The present reaction can be widely applied to convenient synthesis of useful N-substituted oxazolidinones and chiral oxazolidinones.

(10) Direct Catalytic Asymmetric Amination of Aldehydes: Synthesis of Evans, Oxazolidinones and α-Amino Acids.

(11) Conversion of Chiral α-Hydraxino Alcohols and N-Amino Oxazolidinone to Evans Auxiliaries.

(12) Solid-Phase Synthesis of Oxazolidinones by Cycloaddition of Resin-Bound Epoxides with Isocyanates. The first solid-phase synthesis of oxazolidinones by cycloaddition of resin-bound epoxides with isocyanates is described. The present reaction can be widely applied to convenient synthesis of useful N-substituted oxazolidinones and chiral oxazolidinones.

(iii) Protein Binding. 31%.

(iv) Biotransformation. It is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminothiazoylcarboxylic acid metabolite, and the hydroxyethyl morpholine metabolite.

(v) Half-Life. 4.5–5.5 hours.

(vi) Excretion. Renal and fecal (Table 1).

4. Pharmacokinetic Parameter

(i) Absorption. It is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

(ii) Toxicity. Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

(iii) Protein Binding. 31%.

4.1. Available Marketed Formulation

(i) The alarming escalation seen worldwide in the incidence of bacterial resistance to previously effective antibiotics continues to provide the impetus for the medicinal chemist to search for entirely new classes of antibacterial agents, that can cure bacterial infection by novel mechanism. As numerous bacteria have
Figure 2: Chiral resolution method.

Figure 3: Iodocyclocarbamation.

Figure 4: Du PONT asymmetric synthesis.

Figure 5: Oxazolidinones using urea and ethanolamine.
increasingly evidenced the evolution of multiple-
antibiotic resistance, health care provides have been seriously challenged to provide effective therapy for the often life-threatening infection caused by these pathogens. Numerous reviews have recently appeared emphasizing the extent and severity of the resistance problem as it exists today, and the dim prospects envisioned for the future.

(ii) Some of the most problematic organism has been the multi-drug-resistant gram-positive bacteria. These include the highly virulent organism, methicillin-resistant *Staphylococcus aureus* MRSA, and penicillin- and cephalosporin-resistant *Streptococcus pneumoniae*.

(iii) The enterococci have become increasingly of concern; there have been isolated problems of infection with vancomycin-resistant enterococci VREae. A major concern is that VRE will transfer the vancomycin-resistance genes encoded on a plasmid, to much more virulent organism *S. aureus*, as Nobel et al. have demonstrated to be feasible in an experimental setting.

Still another problem microorganism for which resistance has generated considerable medical concern is multidrug-resistant *M. tuberculosis* MDRTB.

This loss of antibacterial activity among drugs once efficacious against these pathogens has led to a summoning from numerous experts for the discovery and development of new antibiotic classes, so that health care practitioners will not be left benefit of effective therapeutic modalities. The oxazolidinone antibacterial agents are capable to provide an answer for these problems in new age.

5. Bacteriostatic versus Bactericidal Nature of Oxazolidinones [20]

Time-kill studies indicate that both Dup-721 (Figure 19) and Dup-105 (Figure 19) were bacteriostatic against all organism tested, expect the diphtheroids but U-100592 (Figure 19) and U-100766 (Figure 19) are bactericidal for *S. pneumoniae* and bacteriostatic for most staphylococci and enterococci.

5.1. Combination Therapy with Other Antibiotics [21]

(i) Antagonism between Dup-721 and ciprofloxacin or norfloxacin was reported for MRSA, *S. epidermidis* and *E. faecalis*.

(ii) In In vivo combination therapy studies, both drugs were found additive with vancomycin, gentamycin, or rifampin against *S. aureus*. Similarly, in a mixed *S. aureus* and *E. coli* infection model combination therapy with aztreonam or gentamycin as well as vancomycin, was found to be effective.

(iii) Oxazolidinones are a new class of totally synthetic antimicrobial agents against multidrug-resistant gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* MRSA, *Staphylococcus epidermidis* MRSE, penicillin-resistant *Streptococcus pneumoniae* PRSP and vancomycin-resistant enterococci VRE [22–25]. Oxazolidinone has:

(a) a novel mechanism of action,
(b) selectively binding,
(c) uniquely binding to the 50S ribosomal subunit,
(d) inhibiting bacterial translation at the initiation phase of protein synthesis,
(e) consequently, the drug would not show cross resistance with existing antibacterial agents.

The unique mechanism of action of oxazolidinones has attracted interest to develop derivatives with potent activity and broad spectrum.

6. Structure Activity Relationship (SAR) [26, 27]

To find out the most potent and comparatively less toxic compounds, we need to do exhaustive study of SAR.

This paper cites the modifications directed for the different parts of the oxazolidinone template as shown in Figure 20. The “A” part manifests oxazolidinone ring, which bears aryl system on the 3rd position of the oxazolidinone ring termed as B region and the 4th position of the aryl group is extended by amine functionality that has been termed as C region. Oxazolidinone ring exclusively possess C5 side chain in the (S)-configuration, which has been optimized for the better efficacy.
Figure 7: Gold catalyzed rearrangement in oxazolidinone synthesis.

Figure 8: N-Boc protected oxazolidinone synthesis.

Figure 9: Nickel catalyzed cycloaddition in oxazolidinone synthesis.

Figure 10: Use of halomethyloxirane, primary amine, and carbonate salt in oxazolidinone synthesis.

Figure 11: Direct catalytic asymmetric amination of aldehydes: synthesis of Evans, oxazolidinones and α-amino acids.

Figure 12: Conversion of chiral α-hydrazino alcohols and N-amino oxazolidinone to evans auxiliaries.
6.1. Synthesized Derivative of Oxazolidinone by Modification

(1) Modifications in the Region A with C5

(i) The thioanalogues of linezolid and eperezolid, 6 (Figure 21) and 7 (Figure 21), do not seem to bind to the 50S ribosomal subunit of the bacteria and thereby are unable to inhibit bacterial protein synthesis. The molecular modeling study supported this unexpected finding of oxazolidine-2-thione [16]. The similar trend of antibacterial activity has been reported in the early investigation for compound 8 (Figure 21), a thioanalogue of DuP 721 [28, 29].

(ii) Quesnelle et al. have reported isoxazolidinone agents having various substitutions at the C-region and most of the compounds have been found to be potent against gram-positive strains [30]. The compounds 9 (Figure 21) and 10 (Figure 21) have shown broad-spectrum antibacterial activity, additionally the sulfoxide 9 exhibited less toxicity compared to the linezolid in a seven-day study in rats.

(iii) Wang et al. have reported series of compounds with scaffolds 11, 12, and 13 (Figure 21) containing chiral 1, 3 oxazinan-2-ones and oxazolidinones as basic core structures having tertiary amines core containing two aryl substituents [31].

(2) Modifications in the Region B and at the C5 [32]. Bosch et al. have reported convenient synthesis of conformationally constrained analog of linezolid 14 (Figure 21) having a tricyclic moiety; however, no antibacterial activity has been disclosed for this compound.

Merck has described novel oxazolidinone derivatives 15 and 16 substituted with cyclopropyl moiety [33]. The compounds 15 (Figure 22) and 16 (Figure 22) exhibited impressive in vitro antibacterial activities against different strains 15.

Selvakumar et al. have reported constrained analogues of linezolid such as hexahydroazolo-quinoxaline and tetrahydroazolo-benzothiazine compounds [34]. Amongst the compound of this class the tetrahydroazolo-benzothiazine and thiocarbamate at C5 side chain 17 (Figure 22) have shown antibacterial activity in the range of 0.25–1 μg/mL against resistant and sensitive gram-positive strains.

Choy et al. from Pfizer reported the synthesis of conformationally restricted oxazolidinone compounds [35]. The compound 18 (Figure 22) was found to be more potent and exhibited broad-spectrum antibacterial activity with MIC values in the range of <0.06–0.25 μg/mL for gram-positive organisms and 1–2 μg/mL for fastidious gram-negative organisms.

(3) Modifications in the Region C with C5 [36]. A series of N-phenyl piperazinyl derivatives of oxazolidinone 19 (Figure 22) in which the nitrogen atom at 4-position of piperazinyl ring is substituted by different cinnamoyl groups. This optimization resulted in few potent compounds, which were found to be active against several gram-positive pathogens. In this class of compound some substituents were well tolerated on the phenyl ring of cinnamoyl group.

There is a reported synthesis of a few Mannich ketones of piperazinyl phenyl oxazolidinone derivatives and their antibacterial activity in various Gram-positive organisms such as Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecalis [37]. A moderately
active compound 20 (Figure 22) has been transformed to active compound 21 (Figure 22). The compound 22 (Figure 22) having cyclohexanone has shown antibacterial activities against various gram-positive strains with MIC values in the range of 1–4 μg/mL, which is comparable to that of linezolid (0.5–4 μg/mL).

Ranbaxy has reported synthesis of oxazolidinones modified at the C region. The optimization of the series afforded a potent compound 23 (Figure 22) (Ranbezolid, RBx7644), which is under clinical development [38]. They have further modified the compound 23 to get the compound 24 (Figure 23), wherein nitrofuran ring is attached to the 2° nitrogen of the aminopiperidine.

In another embodiment a group of scientists from Merck has published a patent describing novel oxazolidinone derivatives possessing cyclopropyl moiety [33]. The disclosed compounds 25 and 26 (Figure 23) have shown excellent in vitro antibacterial activity against broader panel of both susceptible and resistant strains.

Scientists from Orchid have described novel oxazolidinones 27 (Figure 23) having variations in the regions B, C, and at the C5 side chain of oxazolidinone [39].
Pfizer has reported a series of oxazolidinone compounds (Figure 23) containing dihydrothiopyran substituent at the C region and instead of acetic acid other variations such as halogenated amide and thiomamide derivatives were studied at the C5 side chain [40]. The in vitro activities of the C5 modified derivatives were found to be superior compared to the corresponding C5 acetamide derivative. The compounds of this class have shown better antibacterial activities towards Gram-positive \textit{Staphylococcus pneumoniae}, \textit{Enterococcus faecium}, and Gram-negative \textit{Haemophilus influenzae} as compared to the compound (Figure 23) (PNU-288034).

Zhai et al. have reported novel oxazolidinone derivatives having modified C-5 side chain. The compounds 30, 31, and 32 (Figure 24) have shown inferior in vitro antibacterial activities in MIC assay against various strains [41].

Trius Therapeutics has announced the initiation of Phase 1 clinical trials of TR-701 (Figure 24) for the treatment of patients with serious Gram-positive bacterial infections, including those caused by methicillin-resistant \textit{Staphylococcus aureus} and other drug-resistant strains [42].

A group of scientists from Ranbaxy has patented novel substituted phenyl oxazolidinone derivatives [43]. The compound 34 (Figure 24) of this series has shown significant in vitro antibacterial activity in the MIC assay against different strains such as methicillin-resistant \textit{Staphylococcus aureus} \((4.0 \mu g/mL); \text{linezolid} 2.0 \mu g/mL\), vancomycin-resistant \textit{Enterococci} \((2.0 \mu g/mL); \text{linezolid} 2.0 \mu g/mL\).

A series of arylcarboxyl and arylsulfonyl-piperiziny-5-triazolylmethyl oxazolidinones 35 (Figure 24) with improved activity against Gram-positive bacterial clinical isolates than Gram-negative bacterial clinical isolates [44].

Fan et al. have reported triazolyl oxazolidinones as antibacterial agents. Most of the analogues displayed activity superior to the linezolid and the vancomycin in various Gram-positive bacteria [45]. In the antibacterial MIC assay, the compounds 36, 37, and 38 (Figure 24) were found to be potent and further studied for their in vivo efficacies in mice model; however none of the compounds showed in vivo activity.

Selvakumar et al. have reported novel chalcone oxazolidinone hybrids with antibacterial activity. Of these, the compound 39 (Figure 24) containing chalcone substituent in the C region showed significant antibacterial activities with MIC values of \(4 \mu g/mL\) against methicillin-resistant \textit{Staphylococcus aureus} strain [46]. The acetamide group at C-5 was converted to thiocarbamate to get compound 40 (Figure 25), which exhibited in vitro activity in the range of 0.25–2 \(\mu g/mL\) against resistant strains.

Reck et al. at AstraZeneca have reported substituted (pyridin-3-yl) phenyloxazolidinones as antibacterial agents with reduced activity against monoamine oxidase A [47]. The compound 41 (Figure 25) showed excellent activity against Gram-positive bacteria; however the compound 41 lacks the monoamine oxidase A inhibition and inhibits cytochrome P450 (CYP) due to its poor solubility.

Liu et al. have reported novel substituted oxotriazolophenyl derivatives. Of the many compounds described, the compound 42 (Figure 25) has shown potent antibacterial activity against pathogens \textit{Staphylococcus epidermidis}, \textit{Streptococcus pneumoniae}, \textit{Streptococcus enteritidis}, and \textit{Streptococcus nonhemolyticus} at 0.10–6.25 \(\mu g/mL\). O Vara Prasad et al. have reported new series of oxazolidinones with C5 carboxamide functionality, that is, reverse amides, which blocks the bacterial protein synthesis. These compounds have also exhibited less potency against monoamine oxidase enzymes, indicative for the lower side effects. The compound 43 (Figure 25) has shown reduction of myelotoxicity in a 14-day safety study in rodents and compared with linezolid [49].

Rudra et al. have reported series of heterocyclic oxazolidinones as antibacterial agents with identification of RBx 8700 as potent compound [50]. Systematic modification of the linker between the five-membered heterocycle and the piperaizinyl ring of RBx 7644 and its thienyl analogue 44 (Figure 25) resulted in the identification of an expanded spectrum compound.

Reck et al. reported novel acyclic substituted (pyridin-3-yl) phenyl oxazolidinones 45–47 [51] (Figure 25). The acyclic 6-substituted pyridin-3-yl phenyl oxazolidinones 46 and 47 having bulky substituent demonstrated excellent antibacterial activity against Gram-positive organisms, including linezolid resistant \textit{Streptococcus pneumonia} \((1.0 \mu g/mL)\). The compounds with bulkier substituents showed reduced MAO-A activity \((K_i = 40 \mu M; K_i = 19 \mu M)\) compared to the corresponding unsubstituted parent compound 48 (Figure 25) \((K_i < 0.3 \mu M)\) and the improved solubility.

The high-molecular-weight novel oxazolidinone derivatives having variations in the regions B, C, and at the C5 side chain have been patented by a group of scientists from Ferrer International Company [52].

\textbf{(4) Hybrid Molecules} [53]. Morphochem AG has published a patent mentioning oxazolidinone-quinolone hybrid 49 (Figure 26). However, no discloser has been made for their antibacterial activities. Further, in another report they have described different variant of oxazolidinone-quinolone hybrids of type 50. The disclosed derivatives 50 (Figure 26) possess the pharmacophore of quinolone and oxazolidinone linked together through a linker and the hybrid has been used as an antibacterial agent. However, there is no mention of the antibacterial activities for the disclosed oxazolidinone-quinolone hybrids.

\textbf{(5) Computational Studies.} Extensive studies on the syntheses of oxazolidinone antibacterial agents and their SAR have been reported; however only few QSAR studies have been published. The first QSAR study was reported in the year 1999, comprised a 3D-QSAR study on a small data set.
Linezolid blocks the formation of the initiation complex.

Aminoglycosides, macrolides, streptogramins

Electron rich nitrogen atom is well tolerated and often improves safety profile.

Fluorine most of the time improves antibacterial activity.

C-5 acylaminomethyl group is optimal for good activity.

C5-(S)-configuration necessary for antibacterial activity.
sets of two novel series of oxazolidinone antibacterial agents using “Comparative Molecular Field Analysis” (CoMFA), wherein a training set of 17 compounds with two reference compounds have been used. The CoMFA steric, electrostatic fields, and ClogP were used as descriptors, and the activities against methicillin-resistant *Staphylococcus aureus* 88 (MRSA 88) as dependents were developed. The cross-validated r²cv (0.653) and conventional r² (0.984) from the Partial Least Square (PLS) and CoMFA analyses indicated considerable reliability for predicting the antibacterial activities of oxazolidinone antibacterial agents.

The second 3D-QSAR studies, reported by Karki and Kulkarni in the year 2001, used a genetic function algorithm with a data set of 60 compounds. The Qsar models were developed using a training set of 50 compounds and the *in vitro* MIC against *Staphylococcus aureus* SFCO-1. The r² values reported for the models range from 0.629 to 0.732. The predictive ability of the QSAR model was evaluated with a test set of 10 compounds. The results obtained concluded that the antibacterial activity of the 3-aryloxazolidin-2-ones is strongly dependent on the electronic factor as expressed by lowest unoccupied molecular orbital energy (LUMO) and the spatial factor as expressed by density and thermodynamic factors accounted for molar refractivity and the heat of formation. The SAR study by Tokuyama et al. revealed that the antibacterial activity against Gram-positive bacteria including methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci on 5 thiocarbonyl oxazolidinones was significantly affected by the lipophilicity, especially the calculated log P value, the balance between 5-hydrophilic (or hydrophobic) substituents and hydrophobic (or hydrophilic) substituents on the benzene ring (Table 2).

6.2. Oxazolidinone in Clinical Trials

6.2.1. Oxazolidinone: Biological Activity. The development of resistance by the antibiotics in the Gram-positive pathogenic bacteria over the last twenty years and continuing today
has created a need for new antibiotic classes, which may be unaffected by existing bacterial resistance. The oxazolidin-2-ones not only represent a new class with a novel mechanism of action, but also satisfy the requirement for overcoming the resistance mechanisms. Both linezolid and eperezolid, the first chemical candidates, arose from the piperazine subclass, with the first one being chosen further development because of its enhanced pharmacokinetic properties. The main attractive traits of the oxazolidinone series have encouraged further work in the area, and the patent literature reveals that extensive chemical investigation is currently being made. The unexpected early resistance development emphasizes the need for further exploration of features of the oxazolidinone to eliminate these deficiencies. Recently, several changes, involving the C5 side chain as well the N-phenyl heterocyclic ring, give promise for such improvement. Various biological activity show by oxazolidinone derivatives like the following.

(1) *Antibacterial Activity* [54]. Linezolid is an oxazolidinone developed by Pharmacia (formerly Pharmacia & Upjohn) for the treatment of multiresistant Gram-positive infections 187765, 317456. Linezolid resistance due to a 23S rRNA mutation may emerge in Enterococci during therapy with this antimicrobial and may be associated with clinical failure 368652. Following FDA approval, linezolid was launched in May 2000 368526, 368652. In April 2000, the FDA approved linezolid injection, tablets,
Figure 23

X = H, F; Y = H, F
Z = CH, N; Q, S
R = CH₃, CHF₂, CHCl₂

Figure 24

R = m-F-Ph
R = m-NO₂-Ph
R = m-NH₂-Ph
and oral suspension for the treatment of patients with infections caused by Gram-positive bacteria. It is indicated for adults in the treatment of nosocomial pneumonia, community-acquired pneumonia (CAP), complicated and uncomplicated skin and skin structure infections and vancomycin-resistant enterococcus (VRE) infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA), VRE, *faecium* and penicillin-susceptible *Streptococcus pneumoniae* 363503.

Vancomycin resistance was reported in only 0.6 and 3.0% of *Enterococcus faecalis* and *E. faecium*, respectively. Penicillin resistance occurred in 25.1% of *Streptococcus pneumonia*, 4.9% at the high level (≥2 mg/L). The MIC₉₀ for linezolid was 1 mg/L for streptococci and 2 mg/L for enterococci and staphylococci. Using the US FDA- and EUCAST-recommended susceptible breakpoints for linezolid, there were no confirmed reports of linezolid resistance minimum inhibitory concentration (MIC), ≥8 mg/L. The distribution of linezolid MIC values was unimodal and varied between 0.25 and 1 mg/L for streptococci (>90% of isolates) and between 1 and 2 mg/L for staphylococci (>90%) and enterococci (>95%).

Favorable clinical results shown by linezolid prompted many pharmaceutical industries and academic institutions to explore the possibilities of expansion of antibacterial spectrum of this class. A large number of publications, reviews, and patents testify to the interest of the various research groups in the oxazolidinone class of antibacterials. Furazolidone as shown in Figure 27 is the first member of the oxazolidinone class discovered in 1950 and appears to be the initial candidate responsible for the genesis of further work on oxazolidinone antibacterials.

**Table 2**

| S. no. | Compound name | Clinical phase | Sponser | Conditions |
|-------|---------------|----------------|---------|------------|
| (1)   | Rivaroxaban (BAY59-7939) | phase-III | Bayer’s Johnson & Johnson Pharmaceutical Research Development | Deep vein thrombosis (DVT) or Pulmonary embolism (PE) |
| (2)   | Radezolid     | phase-II Complete | Rib-X pharmaceutics | Uncomplicated skin infection |
| (3)   | Torezolid     | phase-II | Trius Therapeutics | Complicated skin and skin-structure infections (cSSSI) |
| (4)   | DA-7218       | phase-III | Dong-A Pharmaceutical | Acute bacterial skin and skin-structure infections (ABSSSI) |
| (5)   | MRX-1         | phase-I | MicuRx Pharmaceutical | Bacterial infection |
| (6)   | Radezolid     | phase-II | Rib-X pharmaceutics | Community-acquired pneumonia |
| (7)   | PNU-100480    | phase- IIa | Pfizer pharmaceutical | Pulmonary Tuberculosis |
| (8)   | RX-1741       | phase- II | Rib-X pharmaceutics | Infectious skin disease |

YC-20 [55] (Figure 28) and linezolid were active against all Gram-positive organisms isolated, including strains resistant to other classes of antibiotics. YC-20 exhibited MIC₉₀ and MIC₉₀ values of <0.5 and 2 mg/L against all isolates. Overall, the activity of YC-20 is slightly superior to that of linezolid. The present study confirms and expands previous findings of the good *in vitro* activity of YC-20 against Gram-positive organisms. YC-20 has a potential role in the treatment of infections caused by Gram-positive pathogens, especially for multidrug-resistant Gram-positive bacteria (Table 3).

Radezolid (RX-1741) [56, 57] (Figure 28) is a novel oxazolidinone with broader spectrum of coverage and increased activity against Gram-positive organisms as compared to other oxazolidinones. Radezolid has recently completed successfully two Phase 2 clinical trials: one for community-acquired pneumonia (CAP) and the second for uncomplicated skin and skin structure infections (Usssi) (Table 4).

The spectrum of activity of torezolid (TR-700) (Figure 28), the active moiety of torezolid phosphate (TR-701), and proposes tentative MIC and disk diffusion breakpoints as well as quality control ranges [58]. The *in vitro* susceptibilities of 1,096 bacterial isolates, representing 23 different species or phenotypic groups, were determined for torezolid, linezolid, cefotaxime, and levofloxacin using Clinical and Laboratory Standards Institute (CLSI) broth microdilution MICs, minimum bactericidal concentrations (MBCs), agar dilution, and disk diffusion testing methods. Torezolid was very active against the majority of Gram-positive strains, including methicillin-susceptible and -resistant *Staphylococcus aureus* (MIC₅₀ = 0.25 μg/mL, MIC₉₀ ≤ 0.5 μg/mL), coagulase-negative staphylococci (CNS; MIC₅₀ = 0.25 μg/mL, MIC₉₀ ≤ 0.5 μg/mL), enterococci (MIC₅₀ and MIC₉₀ ≤ 0.5 μg/mL), and streptococci (MIC₅₀ and MIC₉₀ ≤ 0.25 μg/mL). Based upon MIC₉₀₈, torezolid was 4-fold more active than linezolid against *S. aureus*, coagulase-negative staphylococci, and the enterococci and 8-fold more active than linezolid.

In 2002 AstraZeneca introduced posizolid (AZD2563) (Figure 28). Results indicate that posizolid has excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics [59].

The *in vitro* activity of AZD2563, a novel oxazolidinone, was assessed against 595 Gram-positive cocci, comprising recent surveillance isolates and a collection of resistant
Table 3: Antimicrobial activity of YC-20 against 522 Gram-positive organisms from clinical samples.

| Organism/antimicrobial agent | 50% MIC (mg/L) | 90% MIC (mg/L) | Range MIC (mg/L) |
|-----------------------------|---------------|---------------|------------------|
| Staphylococcus aureus, MSSA (80) |               |               |                  |
| YC-20                       | 0.25          | 0.5           | 0.06–0.5         |
| Linezolid                   | 0.25          | 1             | 0.25–1           |
| Vancomycin                  | 0.5           | 1             | 0.25–1           |
| Ampicillin                  | 1.0           | 2             | 0.25–4           |
| Cefazolin                   | 0.5           | 4             | 0.125–4          |
| evofloxacin                 | 0.125         | 1             | 0.06–2           |
Table 4: Antimicrobial activity of Radezolid against 522 Gram-positive organisms from clinical samples.

| Bacteria               | Linezolid (MICs in mg/L) | Radezolid (MICs in mg/L) |
|------------------------|--------------------------|--------------------------|
| S. pneumonia           | 0.5–2                    | <0.25                    |
| S. pyogenes            | 2–4                      | 0.03–0.125               |
| E. faecalis            | 1–16                     | <0.25–4                  |
| H. influenzae          | 2–64                     | 0.25–2                   |
| S. aureus              | 2–4                      | .5–4                     |
| L. pneumophila         | 4–16                     | 1–4                      |
| C. trachomatis         | 8–16                     | .5–1                     |

The same strains using a broth microdilution assay using either Middlebrook 7H9 containing 0.2% glycerol and ADC enrichment or Mueller–Hinton broth 20. The highest concentration for each compound tested was 32 lg/mL, and each subsequent tube was a twofold dilution of the previous. The M. smegmatis tubes were incubated for 48 h at 37 °C while the other strains were incubated for 24 h and then analyzed. Thiazolyl blue tetrazolium bromide (MTT) was dissolved in MeOH (10 mg/mL) and added to the solution (20 IL) to aid in bacteria visualization.

The in vitro antibacterial activities of the compound and vancomycin, ciprofloxacin, and linezolid as the reference drugs were determined by the conventional agar dilution method using Mueller–Hinton agar medium [63]. The tested Gram-positive organisms included two clinical isolates of S. aureus resistant to methicillin (MRSA), S. aureus ATCC 29737, and S. epidermidis ATCC 12229. Gram-negative bacteria used in the study were E. coli ATCC 8739, S. typhimurium ATCC 1639 and P. aeruginosa ATCC 9027. The tested compounds, vancomycin and ciprofloxacin, were dissolved in DMSO while linezolid was dissolved in water. Suspensions of each of bacteria were prepared to contain approximately 106 colony-forming units (CFU/mL) and applied to plates with twofold serially diluted compounds to be tested in distilled water in concentration ranging from 0.01 to 100 mg/mL and incubated at 37 °C for 18 h. To ensure that the solvent had no effect on bacterial growth, a control test was performed with test medium supplemented with DMSO at the same dilution as used in the experiments.

Minimum inhibitory concentrations (MICs, mg/mL) were determined on Mueller–Hinton (MH) agar with medium containing dilutions of antibacterial agents ranging from 0.12 to 64 mg/mL [64]. The test compounds were dissolved in 20% water in DMSO, while linezolid and vancomycin were dissolved in 40% water in ethanol and water, respectively. The tests were performed using MH agar plates for all staphylococci and enterococci and on MH agar plates supplemented with 5% sheep blood to facilitate the growth of S. pneumoniae, H. influenzae, and M. catarrhalis. The Gram-positive clinical isolates utilized in this study consisted of methicillin-resistant S. aureus (MRSA, n = 1/4 10), methicillin-susceptible S. aureus (MSSA, n = 1/4 10), methicillin-resistant coagulase-negative staphylococci (MR-CNS, n = 1/4 3), methicillin-sensitive coagulase-negative staphylococci (MS-CNS, n = 1/4 6), S. pneumoniae (n = 1/4 3), vancomycin-sensitive (VSE, n = 1/4 6) and vancomycin-resistant (VRE, n = 1/4 4) enterococci. The Gram-negative clinical isolates tested included H. influenzae (n = 1/4 4) and M. catarrhalis (n = 1/4 1). The reference strains, S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, E. coli ATCC 25922, and H. influenzae ATCC 49247 were used as controls. The final bacterial concentration for inocula was 107 CFU/mL and was incubated at 35°C for 18 h. The test compounds were also evaluated against S. aureus ATTC 25923 in MH broth supplemented with 50% human plasma to assess the extent of plasma binding and/or plasma instability. The MIC was defined as the lowest drug concentration that completely inhibited growth of the bacteria.
Against some of the gram-positive bacteria strains tested, the triazole oxazolidinone (Figure 28) PH-027 demonstrated MIC values comparable to or 1- to 2-fold lower that hose of linezolid and vancomycin [65]. In particular, the MIC values of PH-027 against vancomycin susceptible \(E.\ faecium\) (VSE), vancomycin-intermediate-resistant \(E.\ faecalis\) (VIRE), and vancomycin-resistant \(E.\ faecalis\) (VRE) were 0.5, 0.5, and 2 mg/mL, respectively, compared to an MIC of 2 mg/mL demonstrated by linezolid against these strains. However, the MIC’s of vancomycin against the same strains were 4, 8 and >32 mg/mL, respectively. PH-027 demonstrated the most potent antibacterial activity against both sensitive and resistant gram-positive bacteria strains, including MRSA, MSSA, MS-CNS, MR-CNS, PRSP, and enterococci (\(Enterococcus\ faecium\) and \(Enterococcus\ faecalis\)).

The result of in vitro antibacterial activity against a spectrum of resistant and susceptible Gram-positive organisms [66] clearly shows that all compounds (Figure 29) bearing sulfonyl group have good antibacterial activity. Compound showed more potent antibacterial activity than linezolid and vancomycin. Obviously, the introduction of strong electron-withdrawing groups (e.g., CF3, F, and NO2) into the oxazolidinones can confer excellent antibacterial activity especially at the 3rd position of the phenylsulfonyl group, in addition, electron-donating groups (e.g., Cl).

(2) Anticoagulant Activity [67, 68]. Rivaroxaban (BAY 59–7939) (Figure 30) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is
marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho-McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effect lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once daily dosing is possible. 

(3) **Antitubercular Activity.** During the course of investigation in the oxazolidinones antibacterial agent area was identified a subclass with especially potent in vitro activity against mycobacteria [69]. The salient structural feature of these oxazolidinone analogues, U-100480, U-101603, and U-101244, is their appended thiomorpholine. Potent activity against a screening strain of *M. tuberculosis* was determined by U-100480 and U-101603 (MIC = 0.125 mg/mL).

The activities of linezolid, eperezolid, and PNU-100480 were evaluated in a murine model of tuberculosis. Approximately 10^7 viable *Mycobacterium tuberculosis* ATCC 35801 organisms were given intravenously to 4-week-old outbred CD-1 mice [70]. In the first study, treatment was started 1 day postinfection and was given by gavage for 4 weeks. Viable cell counts were determined from homogenates of spleens and lungs. PNU-100480 was as active as isoniazid. Linezolid was somewhat less active than PNU-100480 and isoniazid. Eperezolid had little activity in this model. In the next two studies, treatment was started 1 week postinfection. A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight), PNU-100480 was more active than linezolid, and its efficacy increased with an escalation of the dose. Subsequently, the activity of PNU-100480 alone and in combination with rifampin or isoniazid was evaluated and was compared to that of isoniazid-rifampin. The activity of PNU-100480 was similar to that of isoniazid and/or rifampin in the various combinations tested. Further evaluation of these oxazolidinones in the murine test system would be useful prior to the development of clinical studies with humans.

(4) **Antidepressant or Psychotropic Activity.** Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity [71]. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed [72].
In man, the antidepressant agent 5-(3-methylphenyl)-5-hydroxymethyl-2-oxazolidinone (toloxatone) (Figure 30) on oral dosing was mainly eliminated in urine (80% dose in 12 h).

Plasma concentration of total radioactivity was max (5.8 μg equiv./mL) at 30 min to 1 h after administration and declined rapidly (t1/2, 1.25 h). Unchanged drug accounted for 48, 32, and 13% of plasma radioactivity at 15 min, 1 h, and 6 h, respectively.

The drug was extensively metabolized. The major urinary metabolites were 3-(3-carboxyphenyl)-5-hydroxymethyl-2-oxazolidinone and a glucuronide of toloxatone. A minor urinary metabolite, characterized as a phenolic derivative, was also excreted conjugated.

On the basis of previous laboratory studies AS-8 (5-morpholinemethyl-3-(4-chlorobenzylideneamino)-2-oxazolidinone) was suggested to possess antidepressant-like activity. Forced swim test, learned helplessness, and conflict Vogel's test were performed after three prior administrations of AS-8 (24, 5, and 1h before the test). The data have shown that AS-8 produces moderate antidepressant effect but did not induce anxiolytic-like action. Biochemical data revealed increased brain 5-HT and 5-HIAA levels following AS-8 administration [73]. The combined treatment of rats with AS-8 (100 mg/kg) and amitriptyline (5 mg/kg) or desipramine (1.25 mg/kg) significantly stimulated active behavior in the forced swim test above the level obtained with each of the drug given separately. The present data suggest the potential antidepressant efficacy of AS-8 in conjunction with small doses of tricyclic antidepressants.

(5) Phospholipase Inhibitor [74]. (S)- and (R)-3-dodecanoyl-4-phosphatidylinohydroxyethyl-2-oxazolidinone (1) (Figure 30), which are cyclic analogues of the amide phospholipid 7, were synthesized. The inhibitory activities of these analogues toward phospholipase A2 were compared with that of the amide analogue 7. (S)- and (R)-3-dodecanoyl-4-phosphatidylinohydroxyethyl-2-oxazolidinone (1) were synthesized. The inhibitory activities of these analogues toward phospholipase A2 were compared with that of the amide analogue.

(6) Agriculture Fungicide [75]. 5-Methyl-5-(4-phenoxophenyl)-3-phenylamino-2,4-oxazolidinedione, DPX-JE874, is a new agricultural fungicide under development by DuPont. DPX-JE874 is a member of a new class of oxazolidinone fungicides which demonstrate excellent control of plant pathogens in the Ascomycete, Basidiomycete, and Oomycete classes which infect grapes, cereals, tomatoes, potatoes, and other crops. The synthesis, mode of action, and structure-activity relationships of two types of oxazolidinones, 2-thio-4-oxazolidinones and 2,4-oxazolidinediones, were discussed.

Famoxadone (3-anilino-5-methyl-5-(4-phenoxophenyl)-1, 3-oxazoline-2, 4-dione) (Figure 30), is a new agricultural fungicide recently commercialized by DuPont under the trade name Famoxate [76]. Famoxadone is a member of a new class of oxazolidinone fungicides that demonstrate excellent control of plant pathogens in the Ascomycete, Basidiomycete, and Oomycete classes that infect grapes, cereals, tomatoes, potatoes, and other crops.

Famoxadone is a preventative and curative fungicide recently commercialized for plant-disease control [77]. The molecule and its oxazolidinone analogs are potent inhibitors of mitochondrial ubiquinol: cytochrome c oxidoreductase (cytochrome bc1) and they bind in the Q0 site of the enzyme near the low potential heme of cytochrome b. Inhibitor binding constants for five mutant cytochrome bc1 enzymes from Saccharomyces cerevisiae having single amino acid changes in their apocytochrome b located near the low potential heme were compared with their two parental wild-type enzymes. The five individual amino acid changes altered the inhibition constants for the inhibitors famoxadone, myxothiazol, azoxystrobin, and kresoxim-methyl in dissimilar fashion.

(7) CNS Depressant [78, 79]. A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinemethyl-3-(4-chlorobenzylideneamino)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinemethyl-3-(4-chlorobenzylideneamino)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinemethyl-3-(4-chlorobenzylideneamino)-2-oxazolidinone.

(8) Centrally Acting Muscle Relaxants [80]. The severity of anaemic decerebrate rigidity was quantitatively determined by measuring the frequency of electromyographic potentials in the rat. Some oxazolidinones markedly reduced the severity of this decerebrate rigidity in a dose-dependent manner, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolin-2-one (MLV-6976) being the most potent. In addition to the oxazolidinones, an amino alcohol derivative, (1RS,2SR)-5-methyl-1-phenyl-2-(3-piperidinopropylamino)hexan-1-ol (MLV-5860) also reduced the rat decerebrate rigidity. In the oxazolidinone series, the optical isomers with absolute configuration (S) at the 4-position were more potent than the corresponding (4R)-isomers, while there was no significant difference in their LD50 values. Normal rats and mice receiving MLV-6976 at doses which reduced decerebrate rigidity showed no behavioural changes, impairment of motor coordination only appearing at extremely high doses. MLV-6976 and its derivatives did not affect spinal reflex potentials in cats. MLV-6976 reduced the severity of harmaline-induced tremor in mice in a dose-dependent manner, but slightly augmented tremorine-induced tremor. The frequency of the spike discharges induced by iontophoretically applied glutamate was reduced by MLV-6976 in a dose-dependent manner in rat cortical neurones. The amplitude of miniature endplate potentials of the rat diaphragm was decreased by MLV-6976 only at concentrations greater than 0.1 mM. It is concluded that MLV-6976 acts on the brainstem or/and higher levels of the brain rather than on the spinal cord.
or the peripheral nervous system to reduce the excessive activities of the nervous system.

(9) **Antithyroid Agent** [81]. 5-Vinlyoxazolidine-2-thione (VOT) administered orally to lactating rats was found to be efficiently transferred to the sucklings via the milk. In mothers the exposure to VOT resulted in an increased percentage of neutrophils, a decreased percentage of lymphocytes, and increases in the relative weights of liver and thyroid. Suckling rats showed a decreased number of leucocytes, increases in the relative weights of liver and thyroid and structural changes in the thyroid. Male sucklings were more affected than female pups. The antithyroid effects were clearly related to the maternally administered VOT doses.

RS-Goitrin (Figure 30) can be conveniently prepared by a simplification of the Ettinger procedure. Goitrin is a moderate inhibitor of purified bovine adrenal dopamine beta-hydroxylase [82]. The administration of goitrin leads to a depression of brain norepinephrine and to an elevation of heart and adrenal dopamine.

Brassica vegetables are the major source of glucosinolates in the human diet. Certain glucosinolates are readily converted into goitrogenic species, notably 5-vinlyoxazolidine-2-thione and thiocyanate ion [83]. The effect of dietary Brussels sprouts, a particularly rich source of such glucosinolates, on thyroid function has been examined.

(10) **Antiblastic Activity in Chemotherapy** [84]. Antiblastic activity means retardation of growth. 3-p-(2′, 5′-Dimethoxy-4′-[(N,N-bis-(chloroethyl)amino)benzylideneamino]phenyl)-2-oxazolidinone (GEA 29; BAY a 5850) (Figure 30) and its analogues use as antiblastic agent.

Some other oxazolidinone derivatives are used as anticancer in early clinical trial for example,

(i) 3-nitroso-5-methyl-2-oxazolidinone,
(ii) 3-(2-hydroxy-3-(2-nitro-1H-imidazol-1-yl)propyl)-2-oxazolidinone,
(iii) 4-(4-(bis(2-chloroethyl)amino)-2,5-dimethoxy-phenyl) methylene aminophenyl)-2-oxazolidinone.

(11) **Use in Urinary Tract Infection** [85]. The antimicrobial biliary activity of linezolid, a recently developed antibiotic agent active against Gram-positive bacteria, was tested against Gram-positive uropathogens. Thus, linezolid should be evaluated in a clinical study (Table 5).

D-Cycloserine is a broad-spectrum antibiotic used with other antibiotics to treat various forms of tuberculosis [87]. Its prodrug sodium (R)-4-[(1-methyl-3-oxo-1-butenyl)amino]isoxazolidin-3-one is used as cycloserine analogues. Synonym of this compound is Pentizidone (Figure 30).

### Table 5

| Product name | Use |
|--------------|-----|
| Furaltidone (Figure 30) | Use in UTI |
| 5-(Morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-2-oxazolidinon; | |
| Synonyms | |
| 5-morpholinomethyl-3-((5-nitro-2-furfurylidene)-amino)-2-oxazolidinon; altabactina; alfafur; f-150; furazolina; furazoline; furmethanol | |
| MF | CI3H16N4O6 |
| (n = 67) between 0.5 and 4 mg/L, for methicillin resistant CNS (MRSE) (n = 19) between 0.25 and 2 mg/L, for Enterococcus faecalis (n = 184) between 0.5 and 4 mg/L, for E. faecium (n = 3) 2 mg/L, and for Streptococcus spp. (n = 4) between 0.25 and 1 mg/L, indicating that all strains were susceptible. According to the in vitro activity, linezolid may be considered a promising antibacterial agent | |
| Use in UTI | |
| 6.2.2. Current Research Work on Oxazolidinone. Mathur et al. demonstrated RBX 11760 MICs were in the range of 0.5–1 mg/L for C. difficile isolates, and it demonstrated concentration-dependent killing of C. difficile ATCC 43255 and C. difficile 6387 up to 2–4x MIC (1–2 mg/L). RBX 11760, at concentrations as low as 0.25–0.5 mg/L, resulted in a significant reduction in de novo toxin production as well as sporulation in different C. difficile isolates [88]. In contrast, vancomycin, metronidazole, and linezolid had little or no effect on toxin production and appeared to promote the formation of spores. In the hamster infection model, treatment with RBX 11760 resulted in prolonged survival of animals as compared with vancomycin or metronidazole, which correlated well with the histopathology results. Molecular labelling results suggest that RBX 11760 is a potent inhibitor of bacterial protein synthesis. RBX 11760 showed excellent in vitro and in vivo activity against C. difficile, and it could be a promising novel candidate for future drug development against C. difficile infection. | |
| Skripkin et al. have reported new and improved antibiotics are urgently needed to combat the ever-increasing number of multidrug-resistant bacteria [89]. In this study, we characterized several members of a new oxazolidinone family, Rx-01. This antibiotic family is distinguished by having in vitro and in vivo activity against hospital-acquired, | |
as well as community-acquired, pathogens. We compared
the 50S ribosome binding affinity of this family to that of
the only marketed oxazolidinone antibiotic, linezolid,
using chloramphenicol and puromycin competition binding
assays. The competition assays demonstrated that several
members of the R\textsubscript{X}-01 family displace, more effectively than
linezolid, compounds known to bind to the ribosomal A
site. We also monitored binding by assessing whether R\textsubscript{X}-
01 compounds protect U2585 (Escherichia coli numbering), a
nucleotide that influences peptide bond formation and pep-
tide release, from chemical modification by carbodiimide.
The R\textsubscript{X}-01 oxazolidinones were able to inhibit translation
of ribosomes isolated from linezolid-resistant Staphylococcus
aureus at submicromolar concentrations. This improved
binding corresponds to greater antibacterial activity against
linezolid-resistant enterococci. Consistent with their riboso-
mal A-site targeting and greater potency, the R\textsubscript{X}-01 com-
pounds promote nonsense suppression and frameshifting
to a greater extent than linezolid. Importantly, the gain
in potency does not impact prokaryotic specificity as, like
linezolid, the members of the R\textsubscript{X}-01 family show translation
50% inhibitory concentrations that are at least 100-fold
higher for eukaryotic than for prokaryotic ribosomes.

Hilliard et al. have reported RWJ-416457 is an inves-
tigational pyrrolopyrazolyl-substituted oxazolidinone with
activity against antibiotic-susceptible and -resistant grampositive pathogens [90]. Efficacies of RWJ-416457, linezolid,
and vancomycin against methicillin-susceptible Staphylococ-
cus aureus (MSSA) and community-associated methicillin-
resistant S. aureus (CA-MRSA) in murine skin and sys-
temic infections were compared, as were efficacies against
Streptococcus pneumoniae in a lower respiratory infection.

In staphylococcal systemic infections, RWJ-416457 was
equivalent to twofold more potent than linezolid, with 50%
effective dose values ranging from 1.5 to 5 mg/kg of body
weight/day. RWJ-416457 was two- to fourfold less potent
than vancomycin against MSSA but up to fourfold more
potent than vancomycin against CA-MRSA. In MSSA and
CA-MRSA skin infections, RWJ-416457 demonstrated an
efficacy similar to that of linezolid.

Locke et al. have reported that TR-700 (torezolid), the
active moiety of the novel oxazolidinone phosphate prodrug
TR-701, is highly potent against gram-positive pathogens,
including strains resistant to linezolid (LZD) [91]. Here we
investigated the potential of Staphylococcus aureus strains
ATCC 29213 (methicillin-susceptible S. aureus MSSA) and
ATCC 33591 (methicillin-resistant S. aureus MRSA) to
develop resistance to TR-700. The spontaneous frequencies
of mutation of MSSA 29213 and MRSA 33591 resulting
in reduced susceptibility to TR-700 at 2\textsubscript{x} the MIC were
1.1 \times 10^{-10} and 1.9 \times 10^{-10}, respectively. These values are
\sim 16-fold lower than the corresponding LZD spontaneous
mutation frequencies of both strains. Following 30 serial
passages in the presence of TR-700, the MIC for MSSA 29213
remained constant (0.5 \mu g/mL) while increasing eightfold
(0.25 to 2.0 \mu g/mL) for MRSA 33591. Serial passage of
MSSA 29213 and MRSA 33591 in LZD resulted in 64-
and 32-fold increases in LZD resistance (2 to 128 \mu g/mL
and 1 to 32 \mu g/mL, resp.). Domain V 23S rRNA gene
mutations (Escherichia coli numbering) found in TR-700-
selected mutants included T2500A and a novel coupled
T2571C/G2576T mutation, while LZD-selected mutants
included G2447T, T2500A, and G2576T. We also identified
mutations correlating with decreased susceptibility to TR-
700 and LZD in the rplC and rplD genes, encoding the 50S
ribosomal proteins L3 and L4, respectively.

Resistance to linezolid (LZD) occurs through mutations
in 23S rRNA and ribosomal proteins L3 and L4 or through
methylation of 23S rRNA by Cfr [92]. Here we report novel
L3 mutations, ΔSer145/His146Tyr and ΔMet169-Gly174,
cooccurring with cfr in LZD-resistant Staphylococcus aureus
isolates recovered from a hospital outbreak in Madrid, Spain.
LZD MIC values (16, 32, or 64 \mu g/mL) correlated with
the presence and severity of the L3 mutation. All isolates had TR-
700 (torezolid) MIC values of \leq 2 \mu g/mL.

The crystal structure of the antibiotic drug candidate
RWJ-416457 (Figure 30) (systematic name: N-[(5S)-3-[4-(5,6-dihydro-2H,4H-2-methylpyrrolo [3,4-c]pyrazol-5-
yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]acetamide),
C\textsubscript{18}H\textsubscript{20}FN\textsubscript{5}O\textsubscript{3}, which belongs to the first new class of
antibiotics discovered in the past 30 years, has been determined
at 150 K [93]. Each molecule of this drug donates one hydrogen bond to a neighboring molecule and accepts one hydrogen bond to give (O=C–R–N–H· · · O=C–
R–N–H· · · ), n linkages along the b-axis direction. The
compound contains a pyrrolopyrazole ring, which, owing to
its uncommon structure, has been shown to have particular
effectiveness against multdrug-resistant bacteria.

Locke et al. have reported that staphylococcal resistance
to linezolid (LZD) is mediated through ribosomal mutations
(23S rRNA or ribosomal proteins L3 and L4) or through
methylation of 23S rRNA by the horizontally transferred
Cfr methyltransferase [94]. To investigate the structural
basis for oxazolidinone activity against LZD-resistant (LZD\textsuperscript{R})
strains, we compared structurally diverse, clinically relevant
oxazolidinones, including LZD, dazefloxacin (RX-1741),
TR-700 (torezolid), and a set of TR-700 analogs (including novel
CD-rings and various A-ring C-5 substituents), against a
panel of laboratory-derived and clinical LZD\textsuperscript{R}Staphylococcus
aureus strains possessing a variety of resistance mechanisms.
Potency against all strains was correlated with optimization of C-
and D-rings, which interact with more highly con-
served regions of the peptidyl transferase center binding
site. Activity against cfr strains was retained with either
hydroxyethyl or 1,2,3-triazole C-5 groups but was reduced by
2- to 8-fold in compounds with acetamide substituents.

This phase 4, randomized, double-blind, multicenter
trial compared the efficacy and safety of Zyvox with van-
comycin in the treatment of nosocomial pneumonia proven
to be caused by MRSA, a serious and difficult-to-treat
bacterial infection that is resistant to many antibiotics [95].

The study randomized 1,225 patients between 2004 and
2010. The study was designed as a noninferiority study with
nested superiority, meaning the primary endpoint would be
tested for superiority if it met non-inferiority criteria. In
the study, Zyvox was noninferior and statistically superior
to vancomycin in achieving both clinical and microbiologic
success. The primary endpoint was clinical outcome at
end of study in the per-protocol population. Secondary analyses included clinical outcome at end of treatment in the per-protocol population, clinical outcomes in the modified intent-to-treat population at end of study and end of treatment, microbiologic outcomes at end of study and end of treatment in the per-protocol and modified intent-to-treat populations, and safety and tolerability in the intent-to-treat population. Patients were randomized to receive Zyvox IV 600 mg every 12 hours or vancomycin 15 mg/kg every 12 hours over the course of seven to 14 days; vancomycin doses could be titrated at the investigator’s discretion based on creatinine clearance and vancomycin trough levels.

References

[1] J. Vara Prasad, “New oxazolidinones,” Current Opinion in Microbiology, vol. 10, no. 5, pp. 454–460, 2007.
[2] B. Bozdogan and P. C. Appelbaum, “Oxazolidinones: activity, mode of action, and mechanism of resistance,” International Journal of Antimicrobial Agents, vol. 23, no. 2, pp. 113–119, 2004.
[3] K. E. Brighty, W. Kohlbrenner, and P. R. McGuirk, “Chapter 15. Recent developments in antibacterial resistance mechanisms,” Annual Reports in Medicinal Chemistry, vol. 28, pp. 141–150, 1993.
[4] Y. Luo, L. Liu, L. Li, and Q. Deng, “Chiral resolution of racemic 4-phenyl(benzyl)-2-oxazolidone by use of molecularly imprinted polymers,” Chromatographia, vol. 65, no. 11-12, pp. 675–679, 2007.
[5] S. J. Brickner, “Oxazolidinone antibacterial agents,” Current Pharmaceutical Design, vol. 2, no. 2, pp. 175–194, 1996.
[6] N. Alouane, A. Boutier, C. Baron, E. Vrancken, and P. Mangeney, “Remarkably efficient charcoal-promoted ring-closing carbonylations,” Synthesis, no. 5, pp. 860–864, 2006.
[7] A. Buzas and F. Gagosz, “Gold(I)-catalyzed formation of 5-methylene-1,3-oxazolidin-2-ones,” Synlett, no. 17, pp. 2727–2730, 2006.
[8] R. Robles-Machín, J. Adrio, and J. C. Carretero, “Gold-catalyzed synthesis of alkylidine 2-oxazolidinones and 1,3-oxazin-2-ones,” Journal of Organic Chemistry, vol. 71, no. 13, pp. 5023–5026, 2006.
[9] T. Munegumi, I. Azumaya, T. Kato, H. Masu, and S. Saito, “[3+2] Cross-coupling reactions of aziridines with isocyanates catalyzed by nickel(II) iodide,” Organic Letters, vol. 8, no. 3, pp. 379–382, 2006.
[10] Y. Osa, Y. Hikima, Y. Sato et al., “Convenient synthesis of oxazolidinones by the use of halomethylxirane, primary amine, and carbonate salt,” Journal of Organic Chemistry, vol. 70, no. 14, pp. 5737–5740, 2005.
[11] A. Begevig, K. Juhl, N. Kumarragurubaran, W. Zhuang, and K. A. Jørgensen, “Direct catalytic asymmetric amination of aldehydes: synthesis of Evans oxazolidinones and α-AminoAcid,” Angewandte Chemie International Edition, vol. 41, p. 1790, 2002.
[12] H. P. Buchstaller, “Solid-phase synthesis of oxazolidinones by cyclodaddition of resin-bound epoxides with isocyanates,” Journal of Combinatorial Chemistry, vol. 5, no. 6, pp. 789–793, 2005.
[13] K.-J. Hwang, C.-M. Yu, N.-K. Choi, and K.-H. Park, “A convenient diastereoselective synthesis of oxazolidinone: approach to unusual amino acid statine,” Bulletin of the Korean Chemical Society, vol. 15, pp. 527–532, 1994.
analouges of Linezolid,” *Bioorganic and Medicinal Chemistry Letters*, vol. 16, no. 16, pp. 4416–4419, 2006.

[35] A. L. Choy, J. V. N. Vara Prasad, F. E. Boyer, M. D. Huband, and M. R. Dermyer, “Synthesis and SAR of novel conformationally restricted oxazolidinones possessing Gram-positive and fastidious Gram-negative antibacterial activity, Part 2: Amino substitutions on heterocyclic D-ring system,” *Bioorganic and Medicinal Chemistry Letters*, vol. 17, no. 16, pp. 4699–4702, 2007.

[36] B. B. Lohray, V. B. Lohray, B. K. Srivastava et al., “Oxazolidinone: search for highly potent antibacterial,” *Bioorganic and Medicinal Chemistry Letters*, vol. 14, no. 12, pp. 3139–3142, 2004.

[37] B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannich ketones of oxazolidinones as antibacterial agents,” *European Journal of Medicinal Chemistry*, vol. 39, no. 11, pp. 989–992, 2004.

[38] B. Das, S. Rudra, A. Yadav et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of Rbx 8700,” *Bioorganic and Medicinal Chemistry Letters*, vol. 15, p. 4261, 2005.

[39] S. K. Agrawal, S. S. Pandey, M. M. Samuel, G. Singh, and S. Chithira, “New antibacterial agents,” Pct International Application number WO2005/090339, Orchid Chemicals and Pharmaceuticals, 2005.

[40] A. R. Renslo, G. W. Luehr, S. Lam et al., “Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings,” *Bioorganic and Medicinal Chemistry Letters*, vol. 16, no. 13, pp. 3475–3478, 2006.

[41] X. Zhai, G. G. Zhang, D. H. Jou, J. P. Liu, and P. Gong, “Modification of novel oxazolidinone derivatives at C-5 side chain and their antibacterial activities,” *Acta Pharmaceutica Sinica*, vol. 41, no. 10, pp. 985–989, 2006.

[42] R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko, “The in vitro activity of TR-701, a novel oxazolidinone antibacterial agent,” in *Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC ’07)*, Chicago, Ill, USA, September 2007.

[43] B. Das, S. Rudra, S. Sangita, M. Salman, and A. Rattan, “Oxazolidinone derivatives as antibacterials,” Pct International Application number WO2006/109156, Ranbaxy Laboratories, 2006.

[44] O. A. Phillips, E. E. Udo, A. A. M. Ali, and S. M. Samuel, “Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolymethyl oxazolidinones,” *European Journal of Medicinal Chemistry*, vol. 42, no. 2, pp. 214–225, 2007.

[45] H. Fan, Y. Chen, Z. Jiang et al., “Synthesis and biological evaluation of new N-linked 5-triazolymethyl oxazolidinones,” *European Journal of Medicinal Chemistry*, vol. 43, no. 8, pp. 1706–1714, 2008.

[46] N. Selvakumar, G. S. Kumar, A. Malar Azhagan et al., “Synthesis, SAR and antibacterial studies on novel chalcone oxazolidinone hybrids,” *European Journal of Medicinal Chemistry*, vol. 42, no. 4, pp. 538–543, 2007.

[47] F. Reck, F. Zhou, C. J. Eyermann et al., “Novel substituted (pyridin-3-yl)phenoxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility,” *Journal of Medicinal Chemistry*, vol. 50, no. 20, pp. 4868–4881, 2007.

[48] J. Liu, B. He, A. Yu, and W. Zhou, “Synthesis and antibacterial activity of substituted oxotriazolylphenyl oxazolidinones,” *Chemical Biology and Drug Design*, vol. 70, no. 1, pp. 65–69, 2007.

[49] T. J. Poel, R. C. Thomas, W. J. Adams et al., “Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R-trans-3-[3-fluoro-4-[(1-oxotetrahydrothiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound,” *Journal of Medicinal Chemistry*, vol. 50, no. 24, pp. 5886–5889, 2007.

[50] S. Rudra, A. Yadav, A. V. S. Raja Rao et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of Rbx 8700,” *Bioorganic and Medicinal Chemistry Letters*, vol. 17, no. 24, pp. 6714–6719, 2007.

[51] F. Reck, F. Zhou, G. Zainoun, D. Carcanague, C. Eyermann, and M. Gravestock, “Novel acyclic substituted (pyridin-3-yl) phenyl oxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and improved solubility,” in *Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases*, Munich, Germany, March–April 2007.

[52] M. Cano, A. Palomer, and A. Guglietta, “Oxazolidinone derivatives and use thereof as antibiotics,” Pct International Application numberWO2007/004342, Ferrer International S.A., 2007.

[53] B. K. Srivastava, R. Soni, J. Z. Patel, M. R. Jain, and P. R. Patel, “Oxazolidinone antibacterials and our experience,” *Anti-Infective Agents in Medicinal Chemistry*, vol. 7, no. 4, pp. 258–280, 2008.

[54] J. F. Barrett, “Linezolid pharmacia corp,” *Current Opinion in Investigational Drugs*, vol. 1, no. 2, pp. 181–187, 2000.

[55] Y. Cui, Y. Dang, Y. Yang, S. Zhang, and R. Ji, “Antibacterial activity of YC-20, a new oxazolidinone,” *Journal of Antimicrobial Chemotherapy*, vol. 58, no. 2, pp. 452–454, 2006.

[56] S. Lemaire, K. Kosowska-Shick, P. C. Appelbaum, P. M. Tulkens, and F. Van Bambeke, “Radezolid (RX RX-1741), a novel oxazolidinone oxazolidinone, accumulates, extensively within human macrophages and PMNs and shows activity towards intracellular linezolid linezolid-sensitive and linezolid linezolid-resistant Staphylococcus aureus,” in *Proceedings of the 26th International Congress of Chemotherapy and Infection*, Torranto, Canada, June 2009.

[57] http://www.rib-x.com/pipeline/rxRX-1741.

[58] S. D. Brown and M. M. Traczewski, “Comparative in Vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 5, pp. 2063–2069, 2010.

[59] A. Wookey, P. J. Turner, J. M. Greenhalgh, M. Eastwood, J. Clarke, and C. Sefton, “AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro,” *Clinical Microbiology and Infection*, vol. 10, no. 3, pp. 247–254, 2004.

[60] A. P. Johnson, M. Warner, and D. M. Livermore, “In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci,” *Journal of Antimicrobial Chemotherapy*, vol. 50, no. 1, pp. 89–93, 2002.

[61] B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannichi ketones of oxazolidinones as antibacterial agents,” *European Journal of Medicinal Chemistry*, vol. 39, no. 11, pp. 989–992, 2004.

[62] J. A. Demaray, J. E. Thuener, M. N. Dawson, and S. J. Suchek, “Synthesis of triazole-oxazolidinones via a one-pot reaction
and evaluation of their antimicrobial activity," Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 17, pp. 4868–4871, 2008.

[63] N. Adibpour, A. Khalaj, and S. Rajabalian, "Synthesis and antibacterial activity of isothiazoloyl oxazolidinones and analogous 3(2H)-isothiazolones," European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 19–24, 2010.

[64] O. A. Phillips, E. E. Udo, M. E. Abdel-Hamid, and R. Varghese, "Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones," European Journal of Medicinal Chemistry, vol. 44, no. 8, pp. 3217–3227, 2009.

[65] O. A. Phillips, E. E. Udo, A. A. M. Ali, and N. Al-Hassawi, "Synthesis and antibacterial activity of 5-substituted oxazolidinones," Bioorganic and Medicinal Chemistry, vol. 11, no. 1, pp. 35–41, 2003.

[66] H. Fan, G. Xu, Y. Chen et al., "Synthesis and antibacterial activity of oxazolidinones containing triazolyl group," European Journal of Medicinal Chemistry, vol. 42, no. 8, pp. 1137–1143, 2007.

[67] Oral anticoagulant rivaroxaban (Xarelto) cuts deep vein thrombosis risk by 82%: Bayer, http://www.dancewith-shadows.com/pillscribe/oral-anticoagulant-rivaroxaban-xarelto-cuts-deep-vein-thrombosis-risk-by-82-bayer/.

[68] S. Roehrig, A. Straub, J. Pohlmann et al., "Discovery of novel antithrombotic agent 5-chloro-N-[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl]thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor," Journal of Medicinal Chemistry, vol. 48, no. 19, pp. 5900–5908, 2005.

[69] M. R. Barbachyn, D. K. Hutchinson, S. J. Brickner et al., "Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity," Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 680–685, 1996.

[70] M. H. Cynamon, S. P. Klemens, C. A. Sharpe, and S. Chase, "Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model," Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1189–1191, 1999.

[71] R. R. Ramsay and M. B. Gravestock, "Monoamine oxidases: to inhibit or not to inhibit," British Journal of Pharmacology, vol. 89, no. 1, pp. 219–228, 1986.

[72] H. J. Lewerenz, D. W. Bleyl, and W. Schnaak, "Effects of 5-vinlyoxazolidin-2-thione on lactating rats and their sucklings," Die Nahrung, vol. 36, no. 4, pp. 388–393, 1992.

[73] N. Zenker, L. S. Hubbard, and J. Wright, "Inhibition of dopamine β-hydroxylase by goitrin, a natural antithyroid compound," Journal of Natural Products, vol. 51, no. 5, pp. 862–865, 1988.

[74] M. McMillan, E. A. Spinks, and G. R. Fenwick, "Preliminary observations on the effect of dietary Brussels sprouts on thyroid function," Human Toxicology, vol. 5, no. 1, pp. 15–19, 1986.

[75] M. Artico, G. De Martino, and R. Giuliani, "Research on compounds with antiblastic activity. XL. Synthesis of 3-p-(2',5'-dimethoxy-4'-[(N,N-bis-(N-chloroethyl)-amino)benzylideneamine]-phenyl-2-oxazolidinone (GEA 29 ; BAY a 5830) and its analogues," Il Farmaco; Edizione Scientifica, vol. 26, no. 9, pp. 771–783, 1971.

[76] H. Onda, F. M. E. Wagenlehner, N. Lahn, and K. G. Naber, "In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections," International Journal of Antimicrobial Agents, vol. 18, no. 3, pp. 263–266, 2001.

[77] http://www.chemicalbook.com/ChemicalProductProperty_EN_CB71179461.htm.
is associated with co-occurring mutations in ribosomal protein L3,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 12, pp. 5352–5355, 2010.

[93] E. Y. Cheung, M. L. Peterson, R. Chiarella, and B. M. Foxman, “A novel oxazolidinone anti-biotic: RWJ-416457,” *Acta Crystallographica Section C*, vol. 66, no. 5, pp. o249–o251, 2010.

[94] J. B. Locke, J. Finn, M. Hilgers et al., “Structure-activity relationships of diverse oxazolidinones for linezolid-resistant *Staphylococcus aureus* strains possessing the cfr methyltransferase gene or ribosomal mutations,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 12, pp. 5337–5343, 2010.

[95] New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia, http://www.prnewswire.com/news-releases/new-phase-4-study-shows-higher-rates-of-clinical-and-microbiological-success-for-zyvox-versus-vancomycin-in-mrsa-nosocomial-pneumonia-105422943.html.
Submit your manuscripts at http://www.hindawi.com